Technical Analysis for UTHR - United Therapeutics Corporation

Grade Last Price % Change Price Change
grade F 90.65 2.27% 2.01
UTHR closed up 2.27 percent on Friday, May 17, 2019, on 1.27 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical UTHR trend table...

Date Alert Name Type % Chg
Bullish Engulfing Bullish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Multiple of Ten Bullish Other 0.00%
Outside Day Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 2.27%
NR7 Range Contraction 2.27%
Lower Bollinger Band Walk Weakness 2.27%
Inside Day Range Contraction 2.27%

Older signals for UTHR ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product is Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops oral treprostinil, an orally delivered prostacyclin analog for treatment of pulmonary hypertension; Ch14.18 MAb, an antibody in Phase III clinical trials for the treatment of neuroblastoma; Beraprost 314d, which is entering Phase III clinical trails for the treatment of PAH; PLacental eXpanded cells, which are entering a Phase I trial for the treatment of PAH; and 8H9 MAb, an antibody that is under Phase I clinical trial for the treatment of metastatic brain cancer. Further, the company is involved in the pre-clinical stage of developing TransCon Treprostinil, TransCon Beraprost, and glycobiological antiviral agents for the treatment of infectious diseases, such as Hepatitis C; and engineered lungs and lung tissue, which can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Chemistry Biotechnology Infectious Diseases Chemical Compounds Organic Compounds Alcohols Pulmonary Arterial Hypertension Hepatitis C Neuroblastoma Pulmonary Hypertension Treprostinil Cac All Share Index Chronic And Life Threatening Conditions Oral Therapy Prostaglandins
Is UTHR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 130.0
52 Week Low 88.23
Average Volume 514,482
200-Day Moving Average 115.7578
50-Day Moving Average 107.8236
20-Day Moving Average 97.7125
10-Day Moving Average 93.702
Average True Range 3.373
ADX 35.66
+DI 12.2989
-DI 28.6178
Chandelier Exit (Long, 3 ATRs ) 97.161
Chandelier Exit (Short, 3 ATRs ) 98.349
Upper Bollinger Band 108.0548
Lower Bollinger Band 87.3702
Percent B (%b) 0.16
BandWidth 21.168837
MACD Line -5.1868
MACD Signal Line -4.6698
MACD Histogram -0.517
Fundamentals Value
Market Cap 3.94 Billion
Num Shares 43.5 Million
EPS 8.62
Price-to-Earnings (P/E) Ratio 10.52
Price-to-Sales 3.17
Price-to-Book 2.91
PEG Ratio -0.38
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 96.19
Resistance 3 (R3) 95.99 93.96 95.26
Resistance 2 (R2) 93.96 92.55 94.05 94.95
Resistance 1 (R1) 92.30 91.68 93.13 92.50 94.65
Pivot Point 90.27 90.27 90.68 90.36 90.27
Support 1 (S1) 88.61 88.86 89.44 88.81 86.65
Support 2 (S2) 86.58 87.99 86.67 86.35
Support 3 (S3) 84.92 86.58 86.04
Support 4 (S4) 85.12